Sevelamer is an orally administered weakly basic anion exchange resin which consists of crosslinked polymeric amine that binds dietary phosphate in the gastrointestinal tract. This is approved for the treatment of hyperphosphatemia in adult patients with end-stage renal disease. The binding parameter constants of nonabsorbable sevelamer in its hydrochloride form were determined using the Langmuir approximation for its active pharmaceutical ingredient and 400 mg generic tablet dosage form (Sevel) at pH 4.0, 5.5 and 7.0. The binding parameters were also compared with the innovator product Renagel 400 mg tablet. The results demonstrate the equivalency of the dosage form at each pH in terms of the in vitro binding parameters. The results also demonstrate a shift in the binding mechanism from pH 4.0 to 7.0.
INTRODUCTION
Hyperphosphatemia and secondary hyperparathyroidism are common complications of end stage renal disease (ESRD) that, when untreated, may result in increased morbidity and mortality. 1 Hyperphosphatemia and hypercalcemia have been associated with increased coronary artery calcification. Achieving control of serum phosphorus without increasing serum calcium is an important goal for patients with ESRD. 2 Although calciumbased phosphate binders effectively reduce serum phosphorus and parathyroid hormone concentrations, these agents can lead to hypercalcemia and have been associated with increased vascular calcification. Aluminum hydroxide is a potent phosphate binder, but concern about skeletal, hematological, and neurological toxicity. The phosphorus binder, sevelamer 4 was developed to overcome the limitations associated with the usual management of hyperphosphatemia and secondary hyperparathyroidism (i.e., mineral salts). Sevelamer, a non-absorbable hydrogel, is as efficacious as calcium-based phosphate binders for reducing serum phosphorus but does not cause hypercalcemia or other adverse metabolic effects. Sevelamer also exhibits beneficial effects on lipids, consistently and significantly decreasing LDL cholesterol and increasing HDL cholesterol in most studies. 5 In patients with chronic kidney disease (CKD) stages 3-5D, there is need to avoid the long-term use of aluminum-containing phosphate binders and in patients with chronic kidney disease (CKD) stage 5D, avoiding dialysate aluminum contamination to prevent aluminum intoxication. Sevelamer hydrochloride is a well-tolerated alternative to calcium-or aluminum-containing phosphate binder in the control of serum phosphate in CAPD (continuous ambulatory peritoneal dialysis) patients. Subsequently, the importance of Sevelamer hydrochloride is increasing for hyperphosphatemia.
Renagel tablet (sevelamer HCl) administered orally is the brand product of Genzyme Corporation, UK and is being used for the treatment of hyperphosphatemia.
Pharmacology, pharmacokinetics study, side effects, contraindications, precautions, efficacy, effectiveness, bioequivalence, clinical study and others study of Renagel tablet were approved by the FDA.
This non-absorbable, non-systemic drug is formulated by ACME Laboratories Ltd. Bangladesh as generic drug with a product name Sevel, containing sevelamer hydrochloride 400 mg. The equivalency in terms of efficacy of Sevel tablet (400 mg) was taken into consideration to compare with Renagel (400 mg) tablet using in-vitro study. This invitro equivalence study was performed using Langmuir approximation equation approved by FDA.
Utilizing Langmuir equation the binding affinity constant (K 1 ) and capacity constant (K 2 ) of nonabsorbable sevelamer HCl and its market preparations (Sevel 400 mg tablet) were determined and compared with innovator drug, Renagel 400mg tablet. Thus the present study was designed to evaluate the in-vitro equivalence of Sevelamer hydrochloride generic preparation available in our markets with the innovator product.
MATERIALS AND METHODS
Sevelamer hydrochloride powder (API) and Renagel 400 tablet manufactured by Genzyme Corporation, Ireland, UK, containing sevelamer HCl 400mg were from ACME Laboratories Ltd, The Sevel 400 (B 3001), Sevel 400 (B 3002). Sevel 400 (B 3003) tablet as test products manufactured by ACME Laboratories Ltd, Dhaka, Bangladesh was collected from local market. Potassium monobasic phosphate, N,N-Bis(Hydroxyetyl)-2-aminoethanesulfonic acid (BES), Sodium chloride, Sodium hydroxide, Sodium carbonate, Sodium bicarbonate, Methanol are obtained from Sigma-Aldrich, USA and sulphuric acid was obtained from Merck, Germany. All chemicals were of ACS grade or higher and were used without further purification. Deionized water was obtained from an in-house Barnstead Nanopure System Barnstead/Thermolyne Corporation, Dubuque, IA). Labline heated orbital shaker (Labline 3520 orbital shaker, Hyland scientific, USA) and Ion chromatography (Model no: 881 Compact IC pro 1, Metrohm Ltd., Switzerland), were used in conduction of the study.
Preparation of mobile phase:
1mM NaHCO 3 and 3.2 mM Na 2 CO 3 solution. In a one liter volumetric flask 80 mg NaHCO 3 and 340 mg Na 2 CO 3 were taken and dissolved them with deionized H 2 O made up to one liter. Then the solution was sonicated and filtered through 0.22 micron vacuum filter paper.
Preparation of H 2 SO 4 . In a 1000 ml volumetric flask 5.5 ml conc. H 2 SO 4 was and diluted with 994.5 ml deionized H 2 O. The solution was sonicated and then filtered through 0.22 micron vacuum filter paper.
Preparation of standard phosphate solution.
Three sets of 250 ml volumetric flask were taken. Each set was marked at 8 different phosphate concentration such as 38.7 mM, 30.0 mM, 14.5 mM, 10.0 mM, 7.5 mM, 5.0 mM, 2.5 mM, 1.0 mM. Required amount of KH 2 PO 4 was taken appropriately by calculation for 8 different phosphate concentrations. NaCl 701.28 mg (80 mM ) and N,NBis(hydroxiethyl)-2-aminoethanesulfonic acid (BES) 3198.75 mg (100 mM) was weighed and added for all the volumetric flasks so that all the solutions contain the same concentration of BES and NaCl for maintaining gastrointestinal tract (GIT) chemical environment in-vitro. The final solution was made up to 150 mL by addition of de-ionized water. Such sets of solutions were prepared for three different pH (4.0, 5.5 and 7.0) levels adjusted by 1.0 N hydrochloride acid and 1.0 N sodium hydroxide. Then all the solutions were placed in Labline Heated Orbital Shaker at 37ºC temperatures for 2 hours for maintaining GIT in-vitro. The sample flasks were removed from Orbital Shaker and filtered through a 25 mm, 0.2 micro meter nylon syringe filter. The solutions were fifty times diluted with deionized water. All the drug-free standard samples were prepared in duplicate for different pH levels.
Preparation of sample solution. As per above design to 150 ml phosphate solutions, Sevelamer HCl 400mg (API), Renagel 400mg tablet, Sevel 400 tablet (B 3001), Sevel 400 mg tablet (B 3002) and Sevel 400 mg tablet (B 3003) were added for pH 4.0, pH 5.5 and pH 7.0 accordingly. The pH levels of the solutions were adjusted using 1.0 N hydrochloride acid and 1.0 N sodium hydroxide accordingly. The phosphate binding constants were calculated from the Langmuir approximation. The Langmuir approximation describes the monomolecular adsorption of an adsorbate (phosphate) from solution, at constant temperature onto an adsorbent (sevelamer hydrochloride). 7 The process is described by the
Langmuir equation:
Where Ceq is the concentration of phosphate remaining in mM in solution at equilibrium or the unbound concentration. The x/m is the amount of phosphate bound per weight of polymer in mM/g. The constant K 1 is the affinity constant involved in binding and related to the magnitude of the forces. The constant K 2 is the Langmuir capacity constant and is the maximum amount of that can be bound per unit weight of sevelamer hydrochloride. 6 The affinity constant and Langmuir capacity constants were calculated by performing linear regression on a plot of the unbound phosphate concentration (mM) / binding capacity (mM/g) versus unbound phosphate concentration (mM). The K 1 (= a/b) value is calculated by dividing the slope (a) of the regression line by the intercept (b), the K 2 (= 1/a) value is equal to the inverse of the slope.
RESULTS
The present study was designed to evaluate the in vitro equivalencey of sevelamer hydrochloride generic preparation available in our markets with the innovator product. The equivalency in terms of efficacy of Sevel tablet 400 mg of three different batches B 3001, B 3002 and B 3003 of the generic product designated as Sevel B 3001, Sevel B 3002 and Sevel B 3003, was compared with Renagel 400 mg tablet the innovator product using in vitro study. This in vitro equivalence study was performed using Langmuir approximation equation approved by the FDA. 6 In Langmuir equation the binding affinity constant (K 1 ) and capacity constant (K 2 ) of Sevelamer HCl and its market preparations (Sevel 400 tablet) were determined and compared with innovator drug Renagel 400 mg tablet.
Calibration curve of KH 2 PO 4 . Eight different concentration of KH 2 PO 4 solution were prepared and obtained eight different types of peak areas through ion chromatography. Each solution contains 80 mM NaCl and 100 mM N,N-Bis(hydroxiethyl)-2-aminoethanesulfonic acid (BES) as incubation media for maintaining the chemical environment of GIT invitro. All solutions were kept at Labline orbital shaker for 2.0 hours at 37ºC for maintaining the physical condition of the GIT. Calibration curves were obtained for pH 4.0 (Fig. 2) , pH 5.5 ( Fig. 3 ) and pH 7.0 (Fig. 4) . These different pH levels are observed in different portions in the GIT and were adjusted either by adding (Table 1) . These values specially the slopes and intercepts were used in the calculation of unbound phosphate according to Langmuir approximation equation. The bound concentration was calculated by subtracting the unbound concentration from the initial phosphate concentration before the addition of sevelamer HCl API or its dosage forms. Percentage of unbound and bound phosphate at different pH levels. The unbound phosphate concentration (mM) remaining in each sample was calculated from the linear regression generated plot of area of the phosphate peak against the initial concentration (mM) using intercept and slope of the respective pH according to Langmuir. 6 (Table 17) . The RSQ value, slope and intercept of the regressed plot were determined and the K 1 and K 2 values were obtained from these values respectively for samples, respectively. The combined Langmuir plot of unbound phosphate verses unbound phosphate/binding capacity (Table 17) at pH 4 of Sevelamer HCl (API), Renagel 400 mg tablet, Sevel 400 mg tablet (B 3001), Sevel 400 mg tablet (B 3002) and Sevel 400 mg tablet B 3003 were shown in Fig. 5 . The Langmuir affinity constant (K 1 ), binding capacity constant (K 2 ), RSQ, slope and intercept were very similar for all samples at this pH as shown in Table 18 .
At pH 5.5 using active sevelamer HCl as binding agent the affinity constant (K 1 ) and binding capacity constant (K 2) values were also determined by plotting unbound phosphate concentration (mM)/binding capacity (mM/gm) versus unbound phosphate concentration (mM) at this pH (Table 19) . The RSQ value, slope and intercept of the regressed plot were determined and the K 1 and K 2 values were obtained from these values respectively for samples respectively.
The combined Langmuir plot of unbound phosphate verses unbound phosphate/binding capacity (Table 19 ) at pH 5.5 of Sevelamer HCl (API), Renagel 400 mg tablet, Sevel B 3001 400 mg tablet, Sevel B 3002 400 mg tablet and Sevel B 3003 400 mg tablet were shown in Fig. 6 . The Langmuir affinity constant (K 1 ), binding capacity constant (K 2 ), RSQ, slope and intercept were very similar for all samples at this pH as shown in Table 20 .
At pH 7.0 using active sevelamer HCl as binding agent the affinity constant (K 1 ) and binding capacity constant (K 2) values were also determined by plotting unbound phosphate concentration (mM) / binding capacity (mM/gm) versus unbound phosphate concentration (mM) at this pH (Table 21) . The RSQ value, slope and intercept of the regressed plot were determined and the K 1 and K 2 values were obtained from these values respectively for samples respectively.
The combined Langmuir plot of unbound phosphate verses unbound phosphate/binding capacity (Table 19 ) at pH 7.0 of Sevelamer HCl (API), Renagel 400 mg tablet, Sevel 400 mg tablet (B 3001), Sevel 400 mg tablet (B 3002) and Sevel 400 mg tablet B 3003 were shown in Fig. 7 . The Langmuir affinity constant (K 1 ), binding capacity constant (K 2 ), RSQ, slope and intercept were very similar for all samples at this pH as shown in Table  22 .
At each individual pH, sevelamer hydrochloride powder (working std.), Sevel 400 mg (B 3001), Sevel 400 mg (B 3002), Sevel 400 mg (B 3003) tablet, Renagel 400 mg tablet exhibited very similar binding properties. The affinity constant (K 1 ) of all samples increased gradually form pH 4.0 to 7.0. 
DISCUSSION
The in vitro equivalence study of Sevel 400 mg tablet was compared with reference brand product Renagel 400 mg tablet by maintaining GIT condition by the help of Langmuir approximation approved by FDA. 6 This study was performed to evaluate the efficacy of the generic drug Sevel 400 mg tablet with the innovator product Renagel 400 mg tablet.
The non-linearity of the Langmuir plot and the order of magnitude decrease in the affinity constants (K 1 ) at pH 4.0 can be explained by examining the fraction of each phosphate ion present as a function of pH in dilute solution. This is accomplished by taking into account the hydronium ion concentration at each pH, the pKa of each phosphate ion and the equilibrium reaction. 6 At pH range of approximately 6 -8, monobasic phosphate is in equilibrium with dibasic phosphate. It has been demonstrated that dibasic phosphate is predominately bound species at pH 7.0. At pH 5.5-6.0, the fraction of the monobasic ion increases. The small decreases in the binding affinity constant (K 1 ) demonstrates that the the binding force are weaker at pH 5.5 -6.0. This is due to the decrease in the amount of dibasic phosphate bound and increase in the amount of the monobasic bound. At pH 4.0, the monobasic phosphate ion is predominately present. The affinity constants (K 1 ) are an order of magnitude lower at pH 4.0 than the affinity constants (K 1 ) at pH 7.0. These results suggest that the monobasic ion, which has only one site for binding, is more weakly bound than the dibasic ion, which has two sites for binding. 6 The linearity of the Langmuir plots indicates mono-molecular binding. The relative non-linearity of the Langmuir plots at pH 4.0 may indicate nonmonomolecular binding as a result of monobasic ion. The dibasic binding of phosphate at pH 7.0 and 5.5 of the test and reference were observed where the monobasic binding of phosphate was observed only at pH 4.0. The lower slope of the curve at pH 4.0 also demonstrates the lower binding affinity of monobasic ion.
A possible explanation for the similarities of the Langmuir plot at pH 7.0 and 5.5 is the apparent pKa values. The fraction of each ion at various pH in dilute solution with only phosphoric acid present in water. Sevelamer hydrochloride has an internal charge and hence its own internal ionic strength due to the amines, which are present. This intermolecular charge of sevelamer hydrochloride may shift the pKa of the dibasic anion from 7.2 to a slightly lower value when in solution and in contact with sevelamer hydrochloride. This would cause the fraction of the dibasic ion, at pH 5.5, to be substantially more than predicted. 6 It shows a preference for phosphate over other intestinal anions, such as chloride and bicarbonate. The preference for phosphate is believed to be due to its dianion character, and may also involve hydrogen bonding. The absorption of phosphate in vitro is rapid (less than a minute) relative to the time of passage of such a drug through the small intestine (hours). It has also been found to prevent the absorption of dietary phosphate in vivo and in humans. 
CONCLUSION

Sevelamer
hydrochloride (polyallylamine crosslinked with epichlorohydrin) is a polymeric hydrogel that has been developed as an oral pharmaceutical to prevent the absorption of dietary phosphate by kidney dialysis patients. It has been found to bind to phosphate in vitro, and to do so more effectively than a wide range of other cationic polymers. The results demonstrates that at each individual pH, Sevelamer hydrochloride (API), different batches of Sevel 400 mg tablets and Renagel 400 mg tablet exhibited very similar binding properties showing equivalent kinetic properties in vitro. So, it is evident that a good efficacy of generic drug Sevel 400 mg tablets manufactured by ACME Laboratories Ltd, Dhaka, Bangladesh was observed in terms of its Langmuir binding capacity constants (K 2 ) and affinity constants (K 1 ) as compared to innovator drug Renagel 400 mg tablets. So, Renagel 400 mg tablet manufactured by Genzyme Corporation, Ireland, UK can be substituted by generic product Sevel 400 mg tablet manufactured by ACME Laboratories Ltd, Dhaka, Bangladesh.
